Strahlentherapie und Onkologie

, Volume 188, Issue 2, pp 154–159 | Cite as

Radiotherapy with and without temozolomide in elderly patients with glioblastoma

Original article

Abstract

Background and purpose

The optimal treatment for elderly patients (age ≥ 70 years) with glioblastoma (GBM) remains controversial. We conducted a retrospective analysis in 43 consecutive elderly patients with glioblastoma who either underwent radiotherapy (RT) or radiotherapy plus concomitant temozolomide (TMZ).

Patients and methods

A total of 43 patients (≥ 70 years of age, median age 75.8 years) with newly diagnosed glioblastoma and a Karnofsky performance status (KPS) ≥ 70 were treated with RT alone (median 60 Gy in 2 Gy single fractions) or RT plus TMZ at a dose of 75 mg/m2 per day. The two groups were well-balanced; univariate (log-rank test) and multivariate Cox proportional hazards analysis were used to identify relevant prognostic factors.

Results

The median overall survival (mOS) of the entire patient cohort was 264 days (8.8 months) and the median progression-free survival (PFS) was 192 days (6.4 months). The factors age, sex, previous surgery, KPS, and concomitant use of TMZ had no significant influence on OS/PFS; multivariate analysis was performed to obtain adjusted hazard ratios. TMZ use resulted in a trend toward poorer overall survival when applied concomitantly (314 days compared to 192 days within the TMZ group, p = 0.106). The subgroup analysis revealed that TMZ use resulted in significantly worse survival rates in patients with KPS70 (p = 0.027), but for patients with KPS80 this difference was not detectable.

Conclusion

TMZ should only be used carefully in elderly patients with unfavorable KPS. In this patient cohort, radiotherapy alone is a reasonable option. Standard RT plus concomitant TMZ may be an advantageous treatment option for elderly patients with newly diagnosed glioblastoma who present with good prognostic factors.

Keywords

Radiotherapy Temozolomide Glioblastoma Elderly Treatment outcome 

Strahlentherapie mit und ohne Temozolomid bei älteren Glioblastom-Patienten

Zusammenfassung

Fragestellung

Die optimale Behandlungsstrategie für ältere Patienten (Alter  ≥ 70 Jahre) mit einem Glioblastom (GBM) bleibt kontrovers. Aus diesem Grund haben wir eine retrospektive Analyse mit 43 Patienten durchgeführt, die nach OP/Biopsie entweder eine Strahlenchemotherapie mit Temozolomid (TMZ) erhielten oder nur bestrahlt (RT) wurden.

Patienten und Methodik

43 Patienten  ≥ 70 Jahre (medianes Alter 75,8 Jahre) mit einem neu diagnostizierten Glioblastom und einem Karnofsky-Performance-Status (KPS)  ≥ 70 wurden entweder nur bestrahlt (median 60 Gy in 2-Gy-Einzeldosen) oder erhielten konkomitant Temozolomid 75 mg/m2 pro Tag während der Bestrahlungsserie. Beide Gruppen waren ausgeglichen; zudem wurden univariate und multivariate Analysen durchgeführt, um relevante prognostische Faktoren zu identifizieren.

Ergebnisse

Das mediane Gesamtüberleben der Patientenkohorte betrug 264 Tage (8,8 Monate) und das mediane progressionsfreie Überleben 192 Tage (6,4 Monate). Die Faktoren Alter, Geschlecht, vorausgegangene OP, KPS sowie die konkomitante Gabe von Temozolomid hatten keinen signifikanten Einfluss auf das Gesamt- oder progressionsfreie Überleben, was in der multivariaten Analyse nochmals bestätigt wurde. Die Verwendung von Temozolomid resultierte in einem Trend zu einem schlechteren Gesamtüberleben, wenn es konkomitant verabreicht wurde (192 Tage für Patienten mit Temozolomid verglichen mit 314 Tagen innerhalb der Gruppe der nur bestrahlten Patienten; p = 0,106). Die Subgruppenanalyse ergab, dass Temozolomid bei Patienten mit einem KPS von 70 zu schlechteren Ergebnissen führte als bei Patienten mit einem KPS von 80, bei denen dieser Unterschied nicht mehr beobachtet werden konnte.

Schlussfolgerung

Temozolomid sollte bei älteren Glioblastom-Patienten vorsichtig eingesetzt werden, insbesondere bei jenen, deren Allgemeinzustand reduziert ist. Bei diesen Patienten scheint auch eine alleinige Bestrahlung eine vernünftige Option zu sein. Die Strahlenchemotherapie sollte Patienten vorbehalten bleiben, die günstige prognostische Faktoren aufweisen.

Schlüsselwörter

Strahlentherapie Temozolomid Glioblastom Ältere Patienten Behandlungserfolg 

Notes

Authors’ contributions

MN performed the retrospective analysis, associated statistics, and wrote the manuscript. BS and SBS participated in the preparation and data acquisition of the manuscript. CB participated in the conception as well as the preparation of the manuscript. All authors read and approved the final manuscript.

Conflict of interest

The corresponding author declares that there are no conflicts of interest.

References

  1. 1.
    Fleury A, Menegoz F, Grosclaude P et al (1997) Descriptive epidemiology of cerebral gliomas in France. Cancer 79:1195–1202PubMedCrossRefGoogle Scholar
  2. 2.
    Chakrabarti I, Cockburn M, Cozen W et al (2005) A population-based description of glioblastoma multiforme in Los Angeles County, 1974–1999. Cancer 104:2798–2806PubMedCrossRefGoogle Scholar
  3. 3.
    Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704–710PubMedCrossRefGoogle Scholar
  4. 4.
    Meckling S, Dold O, Forsyth PA et al (1996) Malignant supratentorial glioma in the elderly: is radiotherapy useful? Neurology 47:901–905PubMedCrossRefGoogle Scholar
  5. 5.
    Brandes AA, Compostella A, Blatt V, Tosoni A (2006) Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol 60:256–266PubMedCrossRefGoogle Scholar
  6. 6.
    Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466PubMedCrossRefGoogle Scholar
  7. 7.
    Stupp R, Mason WP, Bent MJ van den et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  8. 8.
    Leitzen C, Schild HH, Bungart B et al (2011) Prediction of clinical course of glioblastomas by MRI during radiotherapy. Strahlenther Onkol 186:681–686CrossRefGoogle Scholar
  9. 9.
    Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  10. 10.
    Kopecky J, Priester P, Slovacek L et al (2010) Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide. Strahlenther Onkol 186:452–456PubMedCrossRefGoogle Scholar
  11. 11.
    Fels F, Kraft JW, Grabenbauer GG (2010) Geriatrics and radiation oncology. part 1: how to identify high-risk patients and basic treatment principles. Strahlenther Onkol 186:411–422PubMedCrossRefGoogle Scholar
  12. 12.
    Marijnen CAM, Berg SMP van den, Duinen SG van et al (2005) Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: a retrospective single institution analysis. Radiother Oncol 75:210–216PubMedCrossRefGoogle Scholar
  13. 13.
    Brandes AA, Vastola F, Basso U et al (2003) A prospective study on glioblastoma in the elderly. Cancer 97:657–662PubMedCrossRefGoogle Scholar
  14. 14.
    Armstrong TS, Gilbert MR (1996) Glial neoplasms: classification, treatment, and pathways for the future. Oncol Nurs Forum 23:615–625 (quiz 26–27)PubMedGoogle Scholar
  15. 15.
    Pierga JY, Hoang-Xuan K, Feuvret L et al (1999) Treatment of malignant gliomas in the elderly. J Neurooncol 43:187–193PubMedCrossRefGoogle Scholar
  16. 16.
    Piccirilli M, Bistazzoni S, Gagliardi FM et al (2006) Treatment of glioblastoma multiforme in elderly patients. Clinico-therapeutic remarks in 22 patients older than 80 years. Tumori 92:98–103PubMedGoogle Scholar
  17. 17.
    Iwamoto FM, Cooper AR, Reiner AS et al (2009) Glioblastoma in the elderly The Memorial Sloan-Kettering Cancer Center experience (1997–2007). Cancer 115:3758–3766PubMedCrossRefGoogle Scholar
  18. 18.
    Kimple RJ, Grabowski S, Papez M et al (2010) Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? Am J Clin Oncol 33:265–270PubMedGoogle Scholar
  19. 19.
    Minniti G, De Sanctis V, Muni R et al (2009) Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91:95–100PubMedCrossRefGoogle Scholar
  20. 20.
    Gerstein J, Franz K, Eberlein K, Rodel C (2010) Radiotherapy with concomitant temozolomide in elderly patients with glioblastoma multiforme. Onkologie 33:56Google Scholar
  21. 21.
    Fiorica F, Berretta M, Colosimo C et al (2009) Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. Arch Gerontol Geriatr 51:31–35PubMedCrossRefGoogle Scholar
  22. 22.
    Roa W, Brasher PM, Bauman G et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588PubMedCrossRefGoogle Scholar
  23. 23.
    Mohan DS, Suh JH, Phan JL et al (1998) Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 42:981–987PubMedCrossRefGoogle Scholar
  24. 24.
    Villa S, Vinolas N, Verger E et al (1998) Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys 42:977–980PubMedCrossRefGoogle Scholar
  25. 25.
    Glantz M, Chamberlain M, Liu Q et al (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266PubMedCrossRefGoogle Scholar
  26. 26.
    Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214PubMedCrossRefGoogle Scholar
  27. 27.
    Chamberlain MC, Chalmers L (2007) A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma. J Neurooncol 82:207–209PubMedCrossRefGoogle Scholar
  28. 28.
    Gerstein J, Franz K, Steinbach JP et al (2010) Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 97:382–386PubMedCrossRefGoogle Scholar
  29. 29.
    Gerstein J, Franz K, Steinbach J et al (2010) Combined radiochemotherapy with temozolomide in patients ≥ 65 years with multiform glioblastoma: clinical outcomes and prognostic factors. Strahlenther Onkol 186 (Sondernr 1):30CrossRefGoogle Scholar
  30. 30.
    Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518PubMedCrossRefGoogle Scholar
  31. 31.
    Minniti G, De Sanctis V, Muni R et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97–103PubMedCrossRefGoogle Scholar
  32. 32.
    Combs SE, Wagner J, Bischof M et al (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70:987–992PubMedCrossRefGoogle Scholar
  33. 33.
    Grabenbauer GG (2010) Long-term survival of patients with glioblastoma multiforme treated with chemoradiation: correlation with MGMT promoter methylation status. Strahlenther Onkol 186:185–187Google Scholar

Copyright information

© Springer Heidelberg Berlin 2012

Authors and Affiliations

  • M. Niyazi
    • 1
  • S.B. Schwarz
    • 1
  • B. Suchorska
    • 2
  • C. Belka
    • 1
  1. 1.Department of Radiation OncologyLudwig-Maximilian-University MunichMunichGermany
  2. 2.Department of NeurosurgeryLudwig-Maximilian-University MunichMunichGermany

Personalised recommendations